Nabsys Partners with European Institutions to Enhance Genetic Disease Research through Advanced Genome Mapping Techniques

Nabsys 2.0, LLC is making strides in advanced genetic research through a new collaboration with one of Europe's foremost institutions, the Leiden University Medical Center (LUMC). This partnership seeks to leverage Nabsys' innovative electronic genome mapping (EGM) technology, particularly its OhmX™ Platform, to address the challenges associated with facioscapulohumeral muscular dystrophy (FSHD). FSHD is a complex genetic disorder that has posed significant difficulties for researchers using traditional molecular techniques.

The Need for Advanced Solutions in Genetic Research

FSHD, a repeat contraction disease, often remains undiagnosed or misdiagnosed due to the limitations of existing diagnostic methods, which, as pointed out by Professor Silvère van der Maarel from LUMC, fail to accurately count the D4Z4 repeat units necessary for a definitive diagnosis. Current standard methods, such as Southern blotting combined with pulsed-field gel electrophoresis, require a high level of technical expertise and present burdens due to the use of radioactivity. This scenario creates a pressing demand for more efficient, cost-effective, and accurate alternatives to current practices.

Collaborating for Innovation

The collaboration between Nabsys and LUMC aims to develop a specialized EGM-based assay capable of improving the genomic analysis of FSHD. Specifically, they will work on implementing the OhmX Platform to count D4Z4 repeats, discriminate haplotypes, and investigate additional complex genetic rearrangements. This partnership will not only accelerate the evaluation and validation of the assay but also ensure the use of well-characterized reference samples.

Justin Bingham, Chief Commercial Officer at Nabsys, expressed the company's excitement about the partnership, emphasizing that EGM technology could become a vital tool in enhancing research accessibility and providing deeper insights into FSHD cases, which have traditionally been challenging due to their ambiguous nature.

Showcasing Technological Advancements at ESHG 2026

At the recent European Society of Human Genetics (ESHG) 2026 Annual Meeting, Nabsys presented a poster demonstrating the capabilities of the OhmX Platform when integrated with CRISPR/Cas9 technology. This integration enhances the detection of repeat expansions across various genetic disorders, showcasing its utility beyond FSHD. Data generated from the study revealed successful detection of repeat expansions in critical genes associated with Fragile X syndrome and Friedreich's ataxia, reinforcing the robustness and reliability of EGM in handling genetic analyses that are typically problematic with standard methods.

The utilization of Nabsys' advanced bioinformatics pipelines, in partnership with Hitachi High-Tech, to optimize assays with CRISPR/Cas9 technology was highlighted as a significant step toward increasing the resolution and accuracy of genetic research. This level of precision allows researchers to tackle complexities that would otherwise remain undetected using conventional sequencing methods.

Looking Ahead

As globalization calls for improved access to genomic technologies, Nabsys has established a growth strategy centered on expanding the reach of its OhmX Platform to researchers globally. Dr. Barrett Bready, the Founder and CEO of Nabsys, noted that their mission includes making EGM more accessible for researchers aiming to conduct pioneering work in genomics.

The journey to redefine diagnostic norms in FSHD and similar repeat expansion disorders is only beginning, but the advancements made by Nabsys and LUMC mark an exciting step forward. With potential implications for better methodologies in clinical practice and research, this collaboration underscores the need to modernize approaches to genetics. As results from their ongoing work emerge, they promise to usher in a new era of precision and understanding in the field of genetic research.

For more detailed insights into their progress, stay tuned to further announcements from Nabsys and LUMC, as they continue to pave the way for innovative solutions in genetics.